ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Esomeprazole

Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.

Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.

Drug pageEsomeprazole: every studyMany companies study it; this page follows only the 122 they lead. All 244 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 2005122 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca920 open or runningphase 4since Sep 12, 2005Mar 16, 2004none ahead
Hanmi Pharmaceuticalits history only50 open or runningphase 3since Sep 4, 2019Dec 8, 2017none ahead
Aralez Pharmaceuticalsits history only40 open or runningphase 1since Jan 11, 2008Jan 11, 2008none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 1since Feb 6, 2018Feb 6, 2018none ahead
Pfizerits history only30 open or runningphase 4since Jan 21, 2016Feb 25, 2012none ahead
Takedaits history only30 open or runningphase 2since Apr 14, 2016Jul 16, 2009none ahead
Torrent Pharmaceuticalsits history only30 open or runningphase 1since Nov 9, 2015Nov 9, 2015none ahead
EMSits history only20 open or runningphase 4since Sep 2, 2015Sep 2, 2015none ahead
Elpen Pharmaceuticalits history only10 open or runningphase 4since Nov 7, 2016Nov 7, 2016none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 3since Oct 31, 2011Oct 31, 2011none ahead

Also a collaborator on its studies: IQVIA RDS, Laboratory Corporation of America, Medidata Solutions, Thermo Fisher Scientific, CISCRP, Arvinas Estrogen Receptor, Parexel and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Feb 27, 2007.

  1. Sep 9, 20102 phase 1 studiesNCT01199328, NCT01210339
  2. Nov 26, 2010Phase 4 study in HeartburnNCT01249651 · 101 enrolled · China
  3. May 16, 2011Phase 1 study in Arthritis, JuvenileNCT01358383 · 28 enrolled · United States
  4. Jun 1, 20112 phase 3 studies in HeartburnNCT01370538, NCT01370525
  5. Jul 18, 2011Phase 4 study in Gastroesophageal RefluxNCT01397084 · 107 enrolled
  6. Dec 15, 2011Phase 1 study in Bioequivalence StudyNCT01494402 · 77 enrolled · Japan
  7. May 8, 2012Phase 1 study in Bioequivalence StudyNCT01595425 · 71 enrolled · Japan
  8. Aug 17, 2012Phase 3 study in Esophagitis, PepticNCT01669811 · 1,398 enrolled · Japan
  9. Dec 21, 2012Phase 3 study in Peptic Ulcer HemorrhageNCT01757275 · 239 enrolled · China
  10. Oct 14, 2013Phase 1 study in Stomach UlcerNCT01964131 · 34 enrolled · Japan
  11. May 28, 20142 phase 3 studiesNCT02157376, NCT02153398
  12. Dec 11, 2015Phase 3 study in Gastroesophageal RefluxNCT02670642 · 877 enrolled · Austria, France, Germany and more
  13. Apr 5, 2018Phase 3 study in Esophagitis, PepticNCT03553563 · 50 enrolled · Japan
  14. Jan 31, 2022Phase 3 study in Gastroesophageal RefluxNCT05267613 · 53 enrolled · United States, Argentina, Australia and more

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

The newest 60 of 92 AstraZeneca leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT05267613Gastroesophageal Reflux · United States, Argentina, Australia and more3CompletedAug 10, 202653
NCT03553563Esophagitis, Peptic · Japan3CompletedDec 27, 202250
NCT02670642Gastroesophageal Reflux · Austria, France, Germany and more3CompletedNov 2002877
NCT02153398Stomach Ulcer · Japan3CompletedApr 201655
NCT02157376Gastrointestinal Hemorrhage · China3CompletedFeb 2016343
NCT01964131Stomach Ulcer · Japan1CompletedDec 201334
NCT01757275Peptic Ulcer Hemorrhage · China3CompletedDec 2014239
NCT01669811Esophagitis, Peptic · Japan3CompletedMay 20141,398
NCT01595425Bioequivalence Study · Japan1CompletedJun 201271
NCT01494402Bioequivalence Study · Japan1CompletedMar 201277
NCT01397084Gastroesophageal Reflux4CompletedJan 2012107
NCT01370538Heartburn · United States3CompletedOct 2011341
NCT01370525Heartburn · United States3CompletedOct 2011340
NCT01358383Arthritis, Juvenile · United States1CompletedJun 201128
NCT01249651Heartburn · China4CompletedJun 2011101
NCT01210339Cardiovascular Diseases · Sweden1CompletedAug 201158
NCT01199328Peptic Ulcer · United States1CompletedNov 201034
NCT01163630Effect of Food · United States1CompletedSep 201024
NCT01159145Pharmacodynamics Study · Japan1CompletedSep 201042
NCT01119768Non-Erosive Reflux Disease · China4CompletedJun 2011305
NCT01094483Platelet Inhibition · United States1CompletedMay 201040
NCT01069939Stomach Ulcer · Japan, Korea, Republic of, Taiwan3CompletedNov 2011427
NCT01015729Peptic Ulcer · Canada1Terminated30
NCT00998075Peptic Ulcer · Canada1CompletedDec 2009138
NCT00992381Healthy · Australia1Completed24
NCT00930215Healthy · Japan1Completed48
NCT00907400Healthy · Sweden1CompletedSep 200948
NCT00761501Healthy Volunteer · Sweden1CompletedDec 200838
NCT00734097Gastroesophageal Reflux · Argentina, Chile, Colombia and more4CompletedOct 2008314
NCT00688428Ulcer1CompletedApr 200884
NCT00687245Gastroesophageal Reflux1CompletedMay 200840
NCT00684190Gastroesophageal Reflux · Sweden1CompletedJun 200830
NCT00676117Healthy · Japan1CompletedJul 200830
NCT00660660Gastroesophageal Reflux · United States4CompletedJul 2008276
NCT00644735Heartburn4CompletedJan 2004750
NCT00641602Heartburn4CompletedAug 20031,000
NCT00637988Barrett Esophagus4CompletedJun 200332
NCT00637845Heartburn4CompletedFeb 2003248
NCT00637559Barrett Esophagus4CompletedApr 200350
NCT00635414Gastroesophageal Reflux4CompletedOct 200260
NCT00633412Stomach Ulcer3Completed400
NCT00634114Esophagitis, Peptic · Japan3Completed540
NCT00633932Esophagitis, Peptic · Japan3Completed602
NCT00633672Stomach Ulcer3CompletedOct 2003400
NCT00629928Stomach Ulcer3CompletedMar 2003800
NCT00629564Gastroesophageal Reflux4CompletedOct 200260
NCT00629512Stomach Ulcer3CompletedDec 2002504
NCT00628953Asthma2CompletedApr 20041,400
NCT00628667Chronic Posterior Laryngitis (CPL)4CompletedMar 2003120
NCT00628342Gastroesophageal Reflux4CompletedAug 2003600
NCT00626535Symptomatic Gastroesophageal Reflux Disease (sGERD)3CompletedFeb 2004500
NCT00626262Gastroesophageal Reflux4CompletedOct 200260
NCT00625495Gastroesophageal Reflux4CompletedNov 200260
NCT00625274Heartburn4CompletedNov 2004100
NCT00608712Postoperative Bariatric Surgery4CompletedAug 2006140
NCT00595517Stomach Ulcer · Japan3CompletedSep 2009395
NCT00542789Stomach Ulcer · Japan3Completed343
NCT00474019Pharmacokinetics · United States, Australia, Belgium and more1Completed42
NCT00444275Gastroesophageal Reflux · France4CompletedOct 20083,029
NCT00441727Stomach Ulcer · United States, Argentina, Australia and more3CompletedAug 20082,426

How it is read

Names in the registry

  • “Esomeprazole”, 72 entries
  • “esomeprazole”, 8 entries
  • “PN400”, 8 entries
  • “Esomeprazole (Nexium)”, 3 entries
  • “HIP1601”, 3 entries

Codes read as this program: D961H, D026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.